• PCT patent lodged
• ‘Smarter’ form of idronoxil
• Opportunity for range of new anti-cancer products.
Sydney, 10 April 2017: Following an announcement on 27 March 2017 about receiving Federal funding for developing drugs products based on a recent discovery referred to as ‘idronoxil-C’, Noxopharm (ASX:NOX) announces today a key step in securing ownership over what it believes is an important drug discovery by lodging a PCT patent application. The Patent Cooperation Treaty (PCT) is an international patent law treaty covering 152 countries and is designed to facilitate global patent grant.
For further information please download PDF attached:
Download this document
